Streetbeat News

AVRO

AvroBio Inc

avrobio.com

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.

Open

1.43

Mkt cap

5.2M

Volume

204K

High

1.44

P/E Ratio

0.17

52-wk high

19.80

Low

1.38

Div yield

N/A

52-wk low

1.38

Wedbush analyst David Nierengarten has downgraded Avrobio (NASDAQ:AVRO) from Outperform to Neutral and set a price target of $2.

Portfolio Pulse from richadhand@benzinga.com

July 12, 2023 | 3:40 pm

Avrobio Inc (NASDAQ:AVRO) shares are trading higher after the company announced it will explore strategic alternatives to maximize shareholder value. This follows a strategic review of its business and a decision to halt further development of its programs. Potential strategic alternatives include an acquisition, merger, business combination, or other transaction. The company did not provide a timetable for the expected completion of the evaluation process.

Portfolio Pulse from Adam Eckert

July 12, 2023 | 3:02 pm

In Wednesday's pre-market session, several healthcare stocks saw significant movement. Gainers included Recursion Pharmaceuticals (RXRX), Healthcare Triangle (HCTI), Cadrenal Therapeutics (CVKD), Aridis Pharmaceuticals (ARDS), Avrobio (AVRO), and Eloxx Pharmaceuticals (ELOX). Losers included Silk Road Medical (SILK), Biodexa Pharmaceuticals (BDRX), BiomX (PHGE), Cingulate (CING), CytoMed Therapeutics (GDTC), and Vincerx Pharma (VINC).

Portfolio Pulse from Benzinga Insights

July 12, 2023 | 1:12 pm

Ault Alliance anticipates $200 million in annual revenue for 2023, causing its shares to trade higher. AVROBIO is exploring strategic alternatives, and Healthcare Triangle has launched an initiative to prevent ransomware attacks in the $35 billion healthcare data market.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 12:34 pm

Avrobio is exploring strategic alternatives, which has led to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 12:18 pm

Trading of AVROBIO shares is set to resume at 7:30 AM ET.

Portfolio Pulse from Charles Gross

July 12, 2023 | 11:11 am

Avrobio has announced that it will cease further development of its programs and will conduct a comprehensive exploration of strategic alternatives. This decision could potentially impact the company's future operations and financial performance.

Portfolio Pulse from Benzinga Newsdesk

July 12, 2023 | 11:11 am

Trading of Avrobio shares has been halted due to pending news.

Portfolio Pulse from Charles Gross

July 12, 2023 | 10:56 am

Avrobio has agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program for cystinosis treatment to Novartis for $87.5 million in cash. Avrobio will retain full rights to its portfolio of HSC gene therapies for other diseases.

Portfolio Pulse from Ryan Gustafson

May 22, 2023 | 7:58 pm

ZIM Integrated Shipping Services shares dropped 13.9% after reporting a YoY decrease in Q1 EPS results and worse-than-expected sales results. Other stocks experienced significant gains and losses during Monday's mid-day session.

Portfolio Pulse from Lisa Levin

May 22, 2023 | 5:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.